The main research area of our group is a high-throughput screening of focused small-molecule libraries, evaluation of candidate inhibitors and structure-based optimization of hit/lead compounds.
The first group of targets are sortase A inhibitors for antimicrobial therapy. Our research efforts are directed at finding and developing more effective and selective therapeutic agents against multi-resistant Gram-positive pathogens with minimal risk of developing drug resistance.
The other group of compounds that we investigate are potential matrix metalloproteinase inhibitors as key targets in the search for effective treatment of tumour metastasis and cancer.
Phone: +371 67808007